此前期招股说明书的信息并不完整，可能会发生变更。已在证券交易委员会备案了与这些证券有关的注册声明，并已生效。此前期招股说明书和随附的招股说明书并不构成对这些证券的出售要约，我们也不会在任何不允许该出售的司法辖区内征集对这些证券的购买要约。

根据424（b）（5）规则提交

注册编号333-279857

须完成，日期为2024年10月31日 

初步招股说明书补充

(截止日期为2024年6月12日的招股说明书) 

股份

普通股

我们正在提供我们的普通股股份，每股面值为0.01美元。

我们的普通股在纳斯达克资本市场上市，或者称为“纳斯达克”，股票代码为“ASPI”。2024年10月30日，我们的普通股在纳斯达克的最后报价为每股6.90美元。

投资我们的证券涉及高度风险。请参阅本招股说明书补充的第S-6页上以及我们在证券交易委员会提交的备妥文件，这些文件已被引用到本招股说明书补充及其附属招股说明书中，以了解在购买我们的普通股之前您应考虑的因素。

证券和交易委员会以及任何州证券委员会均未批准或否决了这些证券，也未核实或审查过本招股说明书补充或随附招股说明书的充分性或准确性。任何相反陈述均构成犯罪行为。

________________________________________

承销商还有权选择在本招股说明书补充稿件日期后30天内按照上述相同条款和条件购买额外股票。

承销商预计将于2024年11月左右将股份交付给购买者。

Canaccord Genuity

2024年11月

目录

招股书补充

招股说明书

关于此招股说明书补充的说明

本招股说明书补充和随附招股说明书涉及我们普通股的发行。在购买我们正在提供的任何股票之前，我们建议您仔细阅读本招股说明书补充、随附的招股说明书、我们授权用于与本次发行相关的任何自由书面招股说明书，以及根据本招股说明书中“更多信息查询处”和“引用特定信息的纳入”标题所描述的参考信息。这些文件包含您在做出投资决定时应考虑的重要信息。

本招股说明书补充材料以及随附的招股说明书是Form S-3（文件号333-279857）上一份“架子”注册声明的一部分，该注册声明于2024年6月12日被证券交易委员会（或“SEC”）宣布生效。本文件包括两部分。第一部分是本招股说明书补充材料，描述了本次发行的具体条款，并补充、更新了随附招股说明书中包含的信息，以及已被引用至本招股说明书补充材料和随附招股说明书中的文件。第二部分，即随附招股说明书，提供更一般性的信息，部分信息可能与本次发行无关。通常情况下，我们提到本招股说明书时，指的是由本招股说明书补充材料和随附招股说明书组成的联合文件。在本招股说明书补充材料中，根据法律规定，我们使用“引用文件”中的信息。这意味着我们可以通过引用这些文件向您披露重要信息。被引用的信息被视为本招股说明书补充材料和随附招股说明书的一部分，并应当同样仔细阅读。当我们未来向SEC提交文件以更新已被引入的文件中的信息时，本招股说明书补充材料中包含或被引入的信息将被视为自动更新和取代。换句话说，在本招股说明书补充材料中包含的信息与随附招股说明书中的信息或被引入本招股说明书补充材料中的信息之间存在冲突或不一致情况时，您应当依赖于后者文件中的信息。

我们及承销商未授权任何人提供除本招股说明书、随附招股说明书或我们授权用于本次发行的任何自由书面招股说明书中所含或并入的信息之外的任何信息。我们和承销商不对其他人可能提供给您的任何信息的可靠性承担责任，也无法保证其可靠性。我们和承销商不在任何未授权进行发行或在该发行或邀约的人未取得资格或向任何人邀约或承诺在任何未获授权的司法管辖区进行买卖我们证券。在美国以外的人士持有本招股说明书和随附招股说明书，必须了解并遵守与普通股发行和在美国以外分发本招股说明书和随附招股说明书相关的任何限制。

您应该假设本招股说明书补充、随附的招股说明书、通过引用纳入本招股说明书补充和随附的文件以及我们授权用于本次发行的任何自由书面说明书中的信息，仅截至这些文件的各自日期时是准确的。我们的业务、财务状况、经营业绩和前景可能自那些日期以来发生了变化。

除非上下文另有说明，本招股说明书中对“我们”、“我们的”和“我们”的引用指的是asp isotopes公司及其整体的合并子公司。

风险因素

投资于我们普通股的股份涉及高度风险。 在您决定投资我们普通股的股份之前，您应该仔细考虑下文中所描述的风险和不确定性，以及我们截至2023年12月31日的年度报告10-k中所述的，由我们随后的SEC提交的修订或补充报告中所涵盖的，被引用并包含于本附录和随附之说明书中的所有其他信息。 我们目前不知道的风险和不确定性，或者我们目前认为不重要的风险和不确定性，也可能对我们的业务，财务状况，营运业绩和前景产生实质影响。 如果发生这些风险中的任何一种，我们的业务，前景，营运结果和财务状况可能会受到重大损害。 在这种情况下，我们普通股的交易价格可能会下跌，您可能会失去您的全部或部分投资。

与我们的普通股、本次发行和其他事项相关的风险

我们普通股的交易价格一直都很波动，而且可能会继续波动，对于各种因素可能会出现宽幅波动的反应，其中一些因素是我们无法控制的。

一般股市和我们普通股的市场经历了极端的波动，这种波动经常与特定公司的营运表现无关。例如，自2022年11月首次公开募股至2024年10月30日我们普通股的最后报价，我们普通股的市场价格从9.23美元的高点下跌至0.32美元的低点。由于这种波动，您可能无法以公开发行价格或更高价卖出您的普通股，您可能会损失部分或全部投资。

如果证券分析师不对我们的业务发表研究或报告，或者他们对我们的股票发表负面评价，我们的股票价格可能下跌。

我们普通股的交易市场在一定程度上将依赖行业板块或金融分析师针对我们或我们业务所发布的研究和报告。无法保证现有的分析师将继续关注我们，或新的分析师将开始关注我们。也无法保证任何覆盖我们的分析师将提供正面报导。缺乏研究报导或不利报导可能会对我们的普通股市价产生负面影响。此外，如果覆盖我们业务的一名或多名分析师降级他们对我们的股票或我们行业其他公司股票的评估，我们股票的价格可能会下跌。

如果您在此次发行中购买普通股，您的投资将立即受到稀释。

这次发行的普通股价格远高于调整后每股普通股的净有形价值。因此，如果您在本次发行中购买我们的普通股，您将以每股价格购买，该价格大大超过本次发行后我们的调整后每股净有形价值。根据每股$的公开发行价格，您将承受每股$的立即稀释，代表本次发行后我们的调整后每股净有形价值与公开发行价格之间的差额。在现有期权或认股权证被行使或限制性股票获准后，您可能会进一步受到稀释。有关您在本次发行后立即会遇到的稀释情况的更多信息，请参见标题为“稀释”的部分。

未来可能会因未来股权或债务发行或其他发行我们普通股的情况而导致未来稀释。

为了筹集额外资本，我们将来可能会提供额外的普通股或其他证券，包括可转换为或可兑换成我们普通股的证券，价格可能不同于本次发行每股价格。我们可能会在任何其他发行中以低于投资人在本次发行中支付的每股价格的价格出售股票或其他证券，未来购买股票或其他证券的投资人可能拥有优于现有股东的权利。增资发行更多的我们普通股或其他可转换成普通股的证券，可能会显著稀释我们的股东。

我们拥有本次发行的净收益的广泛自主权，可能会以您不同意的方式投资或支出净收益，而这些方式可能不会为您的投资带来回报。

尽管我们目前打算按照本说明书补充的「资金用途」部分所述的方式使用此次供款的净收益，但我们的管理阶层将在使用此次供款的净收益上享有广泛裁量权，并可能以并不改善我们的营运结果或增强我们普通股价值的方式花费这笔收益。您将无法影响我们如何使用此次供款的净收益的决定。我们的管理阶层未能有效运用这些基金可能导致财务损失，进而损害我们的业务并导致我们普通股价格下跌。在使用这些资金之前，我们可能以不带来收益或损失价值的方式将来自此次供款的净收益进行投资。

由于我们预计在可预见的未来不会向股东支付任何现金股息，因此，如果有的话，资本增值将是您唯一的获利来源。

我们从未宣布或支付过现金分红派息给我们的资本股。我们目前打算保留所有未来的收益（如果有的话），用来财务我们业务的成长和发展。因此，我们普通股票的资本增值（如果有的话）将是您未来可见的唯一收益来源，而寻求现金分红派息的投资者不应购买我们的普通股。

关于前瞻性陈述的特别说明

本说明书补充内容、随附说明书以及本说明书补充内容及随附说明书所引入的信息中包含根据1933年证券法第27条和交易法第21E条（已修订）的前瞻性陈述，涉及重大风险和不确定性。除了本说明书补充内容、随附说明书以及本说明书补充内容及随附说明书中所含的历史事实陈述之外，包括有关我们的策略、未来营运、未来财务状况、未来营业收入、预期成本、前景、计划和管理层的目标以及预期市场增长的所有陈述均属前瞻性陈述。"Anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would"和类似表达旨在识别前瞻性陈述，尽管并非所有前瞻性陈述均包含这些识别性词语。

在本增补说明书、随附的说明书和本增补说明书及随附的说明书中所录入的信息中，这些前瞻性陈述包括对以下事项的描述：

我们可能无法实际达成我们前瞻性陈述中所披露的计划、意图或期望，您不应过分依赖我们的前瞻性陈述。实际结果或事件可能与我们所作的前瞻性陈述中披露的计划、意图和期望有重大差异。我们在本招股说明书补充文件的警语声明中包括了重要因素，尤其是在“风险因素”部分，以及我们于2023年12月31日结束的年度报告10-k表中，我们随后提交的或补充的美国证券交易委员会文件，已纳入本招股说明书补充文件和附带招股说明书中，这可能导致实际结果或事件与我们所作的前瞻性陈述有重大差异。

您应该完整地阅读本增补说明书、附属说明书以及本增补说明书和附属说明书中所纳入的参考资料，并理解我们实际未来的结果可能与我们的预期有重大差异。我们不承担更新任何前瞻性陈述的义务，除非法律要求，无论是基于新信息、未来事件或其他方面。

本说明书补充资料、随附的说明书以及本说明书补充资料和随附的说明书中所引用的资讯均包括我们从行业刊物、调查和研究以及第三方进行的研究所获得的统计和其他行业和市场数据。本说明书补充资料、随附的说明书和本说明书补充资料和随附的说明书中所引用的所有市场数据涉及许多假设和限制，请勿过分重视此类数据。此外，我们未来表现及我们经营市场的未来表现的预测、假设和估计必然面临高度不确定和风险。

法律事项S-10

我们估计，通过本次发行和销售我们普通股股票，净收益将约为$百万，如果承销商行使其购买额外股票的选择权，则该金额将约为$百万，以上金额在扣除我们支付的承销折扣和佣金及预计发行费用后。

我们打算利用本次发行的净收益作为一般企业用途，包括营业费用、运营资金和资本支出，以加速南非和冰岛浓缩设施的施工。

截至2024年6月30日，我们的现金及现金等价物约为2830万美元，在2024年7月从公开发行普通股中，扣除包括承销折扣、佣金和发售费用后，我们收到约3230万美元的净收益。我们认为，这次发行所得的净收益，加上我们现有的现金，将足以满足未来至少12个月的资金需求。但我们可能会通过股本或债务融资计划筹集额外的所有基金类型。我们未来的资本需求、额外资金的可用性和取得范围，将取决于许多因素，包括这份说明书补充部分中所描述的，并在这份说明书补充部分和相关说明书中引用的“风险因素”一节中。

截至本说明书补充之日期，我们无法确定将从本次发行活动中获得的净收益的所有特定用途。因此，我们的管理层将对从本次发行中获得的净收益的时间和用途享有广泛的裁量权。在我们上述使用本次发行的净收益之前，我们计划将本次发行的净收益投资于短期、利息收入、投资级别的工具、存款证明或直接或保证的美国政府债务。

分红政策

我们从未在普通股上宣布或支付现金分红派息。 我们目前打算保留所有可用资金和未来收益，以支持业务的发展和扩张，我们不预期在可预见的将来支付任何现金分红派息。 未来支付现金分红的决定将由我们的董事会酌情决定，受适用法律约束，并取决于多个因素，包括我们的财务状况、营运结果、资本需求、合约限制、一般业务状况，以及我们的董事会认为相关的任何其他因素。

稀释

如果您参与本次发行，投资我们普通股，您的所有权将立即被稀释，具体程度取决于您在本次发行中支付的每股公开发行价格与本次发行后我们普通股每股经调整净有形资产价值之间的差额。

我们截至2024年6月30日的历史净有形资产价值为770万美元，每股普通股为0.15美元。截至2024年6月30日，我们的历史净有形资产价值是我们的总有形资产减去我们的总负债和非控股权益的金额。历史净有形资产价值每股代表我们的历史净有形资产价值除以截至2024年6月30日未偿还的普通股股份。

扣除由我们支付的承销折扣、佣金和估计的发行费用后，根据本次发行的普通股股票以每股$的公开发行价格，截至2024年6月30日，我们调整后的净有形帐面价值将为$百万，或每股$。这代表对现有股东调整后的净有形帐面价值增加$，对参与本次发行购买我们普通股的投资者则导致调整后的净有形帐面价值每股减少$。本次发行购买我们普通股的投资者的每股稀释受到投资者支付每股公开发行价格后的调整后的净有形帐面价值减去本次发行后的调整后每股净有形帐面价值的影响。以下表格说明了这种对于参与本次发行购买我们普通股的投资者的稀释，未考虑承销人行使其购买额外股份选择权的情况。

如果承销商完全行使其购买额外股份的选择权，调整后的净有形帐面价值将提高至每股 $，对现有股东每股增加 $，对在本次发行中购买我们普通股的投资者每股立即稀释 $。

以上表格基于2024年6月30日截至的52,132,833股普通股，不包括：

在期权或认股权被行使的情况下，将发行新的期权、认股权或限制性股票奖，或在上述事件或未来其他任何原因下发行额外的普通股，将对参与本次发行的投资者造成进一步稀释。

对于我们普通股的非美国持有人，美国联邦所得税和遗产税的考虑事项

以下是有关美国联邦所得税和遗产税的材料讨论，涉及非美国持有人拥有和处分我们普通股时的税务考虑。在本讨论中，"非美国持有人" 一词是指我们普通股的有利拥有人（除了合伙企业或其他分配实体），并且不是联邦所得税目的地的人：

本论言基于美国1986年入法正美式或修改之的现行程序。我借用作为「程序」来澫，及所有现行及已采变美国金展规注釛度贴程、现行行政规宠2021年们依满故表神和历利决誉后有效于程序的明细贴程，而个判话袋，可能会威背性费效。任一变更或威背费效可以复诊未来的不同观议和确。多起，没有供府程序会无意志挖战方格中的程序费效讨论之一或曝，以至于可能威背费效作。

本讨论仅针对持有我们普通股的非美国持有人，该股票作为资本资产（一般而言，持有以投资为目的的财产）。本讨论不涵盖所有与个别非美国持有人的情况相关的美国联邦所得税和遗产税的所有方面，也不涵盖最低替代税、对净投资收入征收的医疗保险税，以及美国、州或非美国税的任何方面。本讨论还不考虑可能适用于非美国持有人的任何具体事实或情况，也不涵盖适用于特定非美国持有人的特殊税收规定，例如：

此外，此讨论并未涉及合伙企业或通过合伙企业或其他用于美国联邦所得税目的的穿透性实体持有其普通股的合伙人或其他人士的税务处理。将持有我们的普通股的合伙企业合伙人或其他穿透性实体应就通过合伙企业或其他穿透性实体购买、持有和处置我们的普通股的税务后果咨询其自己的税务顾问，适用时。

有意投资者应就购买、持有和处置我们的普通股涉及的美国联邦、州、地方和非美国收入以及其他税务问题咨询自己的税务顾问。

分红派息

如果我们对我们的普通股支付分红派息，则该分红一般将依据美国联邦所得税原则，从我们的当前或累积盈利中支付，该支付通常将构成分红。 如果分红超过我们的当前和累积盈利，则超额部分将被视为非美国持有人投资的免税退回，最多不超出该持有人对普通股的税基。 任何剩余的超额部分将被视为资本利得，适用于下文“-出售普通股的利得”标题下所描述的税务待遇。

非美国股东所获的股息通常将受到美国联邦所得税的30%扣缴，或者可能根据美国与该股东所居住国家之间的适用所得税协定而订定的较低税率。索取我们普通股所获得适用所得税协定条款的非美国股东通常应提供完整填写的IRS Form W-8BEN或W-8BEN-E（或后续表格）并符合相关认证和其他要求。符合所得税协定规定的非美国股东可通过及时提交适当的要求给IRS来获得退税或抵免任何过多扣缴的金额。

若非美国持有人将分红视为与其在美国内进行的业务有实质联系，且如果适用的所得税协定规定如此，并归因于非美国持有人在美国内设立的永久性机构或固定基地，则通常免征30%的扣缴税。若非美国持有人符合适用的证明和披露要求。然而，此类美国有实质联系的收入将以净利润基础按照与《税法》中所定义的美国人适用的相同美国联邦所得税率征税。任何一家非美国持有人收到的有实质联系的美国收入，若其为公司，也可能根据美国与其居住地国家之间的适用所得税协定，在某些情况下，受到30%的“分支利润税”或可能由协定所指定的更低税率的纳税。

建议非美国持有人咨询其自己的税务顾问，以了解其根据适用所得税条约的权利。

普通股份处置收益

非美国持有人一般在出售我们的普通股所认识的利得上，通常不会受到美国联邦所得税的税款影响，除非：

资讯报告和备份扣缴

我们必须每年向美国国税局和每位非美国持有人报告支付给该持有人的普通股的分红总额和相关分红的扣缴税额（如有）。非美国持有人可能需要遵守特定的认证程序，以确定持有人不是美国人（根据《税法》定义），以避免对我们的普通股分红进行可适用税率（目前为24％）的备用扣缴。通常，非美国持有人将遵守这些程序，如果提供适当签署的IRS W-8BEN或W-8BEN-E表格（或其他适用的W-8表格）或以其他方式符合证明要求以确定其为非美国持有人，或另外建立豁免。按照上述“- 分红”标题下述及的正在扣缴的美国联邦所得税的非美国持有人支付的分红，通常将免于美国的备用扣缴。

对于非美国持有人通过或通过任何美国或外国经纪的美国办事处处置我们普通股所得的情况，一般将适用资料报告和备份扣缴，除非持有人证明其为非美国持有人并符合某些其他要求，或者以其他方式确立豁免。一般来说，对于非美国持有人通过经纪的非美国办事处在美国以外进行业务的处分所得支付，将不适用资料报告和备份扣缴。然而，就资料报告而言，透过持有大量美国拥有权或业务的非美国办事处进行处分通常将被视为与透过经纪的美国办事处进行处分类似。非美国持有人应咨询其自己的税务顾问，以了解资讯报告和备份扣缴规则对其的应用。

信息报表的复本可能根据特定条约或协议的规定提供给非美国持有人居住或注册地的税务机构。

备用代扣不是额外的税项。相反，根据备用代扣规则扣除的任何金额，从向非美国持有人的付款中扣除的金额，如果有必要，可以向IRS提出适当的申请及时退还或抵免非美国持有人的美国联邦所得税责任。

FATCA

《代码中称为外国账户税收合规法案（FATCA）的条款通常对我们的普通股股息及出售或处分所得施加30%的预扣税，除非支付给外国实体，除非（i）该外国实体是“外国金融机构”，该外国实体履行某些尽职调查、报告、预扣税和证明义务，（ii）如果该外国实体不是“外国金融机构”，则该外国实体识别其某些美国投资者，或（iii）该外国实体在FATCA下另有规定获得豁免。

根据FATCA，通常适用于我们普通股的分红支付。尽管FATCA还适用于我们普通股出售或其他处置所得款项的扣缴，根据美国财政部提议的法规，不需要对总收入支付的款项进行扣缴。尽管该法规尚未最终确定，但适用的扣缴机构可以在最终法规出台前依赖提议的法规。

如果在涉及我们普通股的任何支付中，根据FATCA有必要扣缴税款，则没有其他必须扣缴（或其他本应享有扣缴减免率）这种支付的投资者可能需要向IRS寻求退款或信用。美国与相应外国国家之间的政府间协议可能修改本部分所述要求。非美国持有人应咨询他们自己的税务顾问，了解FATCA对他们在我们普通股中的投资以及持有我们普通股的实体可能带来的潜在影响。

联邦遗产税

我们共同持有的股票或被视为由在死亡时为非美国持有人（根据美国联邦遗产税目的特别定义）拥有的个人持有，将被纳入该个人的美国联邦遗产税目的总资产，因此可能需缴纳美国联邦遗产税，除非适用的遗产税或其他条约另有规定。

有关美国联邦税务考量的前述讨论仅供潜在投资者参考。不构成税务建议。潜在投资者应就购买、持有和处置我们的普通股的美国联邦、州、地方和非美国税务后果，包括拟议法律变更的后果，咨询其自己的税务顾问。

包销商承销

根据本补充说明书日期的承销协议条款和条件，下文所列承销商已同意购买我们同意卖给承销商的下面指示数量的股份：

承销商有义务在本说明书补充中提供的所有普通股中买入并支付所有这些股份。但是，如果承销商选择购买以下描述的附加股份的选择权，则承销商无需购买或支付这些股份。

承销商最初建议将普通股的部分股份直接以本招股书补充内容封面列明的发行价格向公众发售，另一部分以不超过每股$ 的让步价格向某些经销商发售。在普通股的首次发行后，发售价格和其他销售条款可能不时被承销商修改。

我们已向承销人授予选择权，自本说明书补充说明日期起计30天内行使，以公开发售价格购买本说明书补充说明封面页上列出的普通股额外股份，扣除承销折扣和佣金。

以下表格显示每股的公开发行价、包销折扣和佣金、以及在扣除开支前我们获得的款项。这些金额是根据假设包销人行使购买额外普通股的权利，而且不论有无行使全部权利。

本公司预计支付的发行费用，不包括承销折扣和佣金，大约是$。我们已同意就特定费用对承销商进行补偿，包括与金融行业监管局有关的任何事宜，以及本次发行的股份符合州证券法的资格，总金额最高为$100,000。

我们的普通股在纳斯达克上市，交易标的为“ASPI。”

我们和所有董事和高级主管（“锁仓方”）已同意，在某些例外情况下，在本招股说明书补充之日起90天内（“限制期”之日前）未经承销商事先书面同意，我们和他们将不会公开进行，或者不会公开透露有意于该期结束之前。

前段描述的限制不适用于由锁定方进行的此类转让或处置。

此外，上述限制不适用于某些情况，包括：

承销商依其独立判断，可以随时全部或部分释出上述禁售协议所描述的普通股和其他证券。

为了促进普通股的发行，承销商可能会进行稳定、维持或以其他方式影响普通股价格的交易。具体来说，承销商可能会卖出比其在承销协议下买入的股票份数更多的股份，从而形成空头头寸。如果空头头寸不超过承销商按照选择权应该购买的股份数，则所谓的空头卖空就是有担保的。承销商可以通过行使选择权或在公开市场上购买股票来结束有担保的空头卖空。在决定来源以结束有担保的空头卖空时，承销商将考虑，除其他事项外，股份的公开市场价格与选择权下可获得价格之间的比较。承销商还可能卖出超过选择权的股份，从而形成裸空头头寸。承销商必须通过在公开市场上购买股份来结束任何裸空头头寸。如果承销商担心定价后公开市场对普通股价格可能产生向下压力，影响购买本次发行股票的投资者，则更有可能形成裸空头头寸。为了进一步促进这次发行，承销商可以在公开市场上竞标并购买普通股，以稳定普通股价格。这些活动可能使普通股的市场价格升高或保持在独立市场水平之上，或防止或减缓普通股市场价格下跌。承销商不必参与这些活动，也可以随时终止其中任何一项。

我们和承销商已同意相互赔偿某些责任，包括证券法下的责任。

承销商及其联属公司过去已为我们、我们的子公司和联属公司提供过各种投资银行、商业银行和其他金融服务，未来可能继续提供，而这些服务已经收取过惯例费用，未来可能继续收取。

在进行本次发行的承销商或贩售团成员之一（如有）维护的网站上，可能提供电子形式的说明书补充资料。

销售限制

欧洲经济区

就欧洲经济区的每一个成员国和英国（各自为“相关国家”）而言，在当有关国家出版经相应当局批准的有关证券的计划书之前，不得根据有关证券向公众公开发售，除非这已根据《计划书法》在该相关国家得到批准或在其他相关国家得到批准并通知在该相关国家的当局，一切均按照《计划书法》的规定，该相关国家可能根据计划书法的以下豁免条款随时向该相关国家公众发行证券：

倘若此等股票供应并无需我们或我们的代表根据《说明书规例》第3条发布招股说明书，或根据《说明书规例》第23条补充招股说明书。

根据本条款的目的，“向公众提出”这个术语与相关国家的任何股票之间的表达，表示通过任何形式和方式传达有关要约条款和拟提供的任何股份的充足信息，使投资者能够决定购买任何股份，“招股书规定”这个术语指的是规定（EU）2017/1129（经修订） 。

英国 

每位承保人均表示并同意：

法律问题

本次我们提供的普通股的股份有效性正在由Blank Rome LLP审核。Goodwin Procter LLP在这次发行中担任承销商的法律顾问。

专家

ASP同位素公司及其子公司截至2023年和2022年12月31日的合并资产负债表，以及相关的合并损益表、综合损益表、股东权益变动表和现金流量表，已由独立注册的会计事务所EisnerAmper LLP进行审计，其报告已纳入参考，报告包含关于存在重大疑问有关公司能否作为持续经营实体的解释段落。这些基本报表已纳入参考，依赖该会计和审计专家凭其授权给出的专业报告。

更多资讯可于以下地方找到

我们向证券交易委员会提交年度、季度和当前报告、代理人声明和其他资讯。我们的SEC提交公开在互联网上证券交易委员会的网站www.sec.gov 可用。我们向证券交易委员会提交的某些信息的副本也可以在我们的网站www.aspisotopes.com上获得。证券交易委员会的网站和我们的网站并不属于本补充说明书的一部分，也不被纳入本补充说明书的参考资料。

本说明书补充资料是我们向SEC提交的登记申明书的一部分。 该登记申明书包含比这份说明书补充资料和随附的说明书更多关于我们和证券的资讯，包括某些展示和附表。 您可以从SEC的网站和我们的网站获取登记声明书的副本。

透过引用纳入特定资讯

证交所允许我们将已提交给证交所的大部分信息纳入本增补说明书和随附的说明书，这意味著我们可以通过让您参考那些已公开的文件向您披露重要信息。我们纳入本增补说明书和随附的说明书的信息被认为是本增补说明书和随附的说明书的一部分。由于我们正在将未来提交给证交所的文件纳入参考，本增补说明书和随附的说明书将不断更新，而未来的提交可能修改或取代包含在本增补说明书和随附的说明书中的部分信息。这意味著您必须审查我们纳入参考以判断本增补说明书、随附的说明书或以前纳入参考的任何文件中的任何声明是否已经被修改或取代。

本招股说明书和随附的招股说明书通过引用以下列出的文件（在每种情况下，均不包括向美国证监会提交的文件或其中未被视为向美国证监会提交的文件的部分），直至证券注册声明的发行终止或完成为止：

我们还通过引用将我们可能在完成或终止发行前根据《交易所法》第13(a)、13(c)、14或15(d)条向证券交易委员会提交的其他文件纳入本招股说明书补充资料和随附的招股说明书中，但排除未与证券交易委员会提交的任何信息。 任何包含在先前已提交文件中的声明被视为根据本招股说明书补充资料和随附的招股说明书的目的进行修改或取代，以便在本招股说明书补充资料和随附的招股说明书中包含的声明，或在随后提交的文件中也被纳入本招股说明书补充资料和随附的招股说明书的声明，修改或取代该声明。

我们将免费向收到本招股说明书补充和随附招股说明书的每位个人提供任何被引用的信息的副本。如需此类文件，请致函或口头要求至以下地址：

asp isotopes公司。

华盛顿特区宾夕法尼亚大道601号

南楼，900套房

华盛顿特区20004

(202) 756-2245

注意：公司秘书

您还可以免费访问本招股说明书补充中通过参考而纳入的文件，可通过SEC网站www.sec.gov或我们的网站www.aspisotopes.com免费获取。SEC网站或我们的网站上包含的信息不属于也不被纳入本招股说明书补充，您不应将SEC网站或我们的网站上的信息视为本招股说明书补充的一部分。

根据424（b）（5）规则提交

文件编号333-279857

招股说明书

$50,000,000

普通股

优先股

债务证券。

权证

单位

我们可能不时提供并出售本招股说明书中描述的任何证券，可以单独或与其他证券组合，以总计高达5000万美元的标售价进行一次或多次发行。

本招股说明书提供了我们可能提供的证券的一般描述。我们将在本招股说明书的一个或多个附录中提供证券的具体条款。招股说明书附录还将描述这些证券将以特定方式进行的具体情况。我们还可能授权一个或多个自由撰写招股说明书与这些发行相关的提供给您。招股说明书附录和任何相关的自由撰写招股说明书可能添加、更新或更改本招股说明书中包含的信息。在您投资我们的任何证券之前，请仔细阅读本招股说明书、适用的招股说明书附录、任何相关的自由撰写招股说明书以及参考的文件。本招股说明书不能用于出售任何证券，除非附有适用的招股说明书附录。

我们的普通股在纳斯达克资本市场（“纳斯达克”）上市，股票代码为“ASPI”。截至2024年5月30日，我们的普通股最后报告交易价格为每股5.43美元。如适用，相关的招股说明书将包含有关在纳斯达克或其他证券市场或交易所上市的任何其他证券，如果有的话。

投资我们的证券涉及高风险。请参阅本招股说明书第7页上的“风险因素”以及任何补充材料，了解在与我们的证券的投资有关的应考虑的信息的讨论。风险因素根据本招股说明书第7页及纳入本招股说明书的文档，经适用的招股说明书补充更新，任何相关的自由撰写招股说明书以及我们未来向证券交易委员会提交并纳入本招股说明书的文件，详细讨论我们建议您在决定购买我们的证券之前仔细考虑的因素。

我们可能直接向投资者出售这些证券，也可能通过不时指定的代理商或承销商进行出售。有关销售方法的更多信息，请参阅题为“"分销计划”的部分。如果有任何承销商参与向交付本招股说明书的证券出售，这些承销商的名称以及任何适用的佣金或折扣将在招股说明书的补充中列出。此类证券的公开价格和我们预计从此次销售中收到的净收益也将在招股说明书的补充中列出。

证券交易委员会或任何州证券委员会尚未批准或否认这些证券或确定本招股说明书是否真实或完整。任何相反的陈述均构成犯罪。

本招股说明书日期为2024年6月12日

目录

关于本招股说明书

本招股说明书是我们根据1933年修正案股票法案向证券交易委员会（“SEC”）注册的一部分，采用“货架”注册程序。根据这一货架注册程序，我们可能不时地以高达5000万美元的总发行价，通过本招股说明书中描述的各种证券的任何组合，进行一项或多项发行和销售。

本招股说明不得用于提供和销售证券，除非附有适用的招股说明。

本招股说明书提供了我们可能发行的证券的一般描述。每次我们根据本招股说明书卖出证券时，我们将提供一个包含有关该发行条款的具体信息的招股说明书补充。我们还可能授权提供一个或多个自由书面招股说明书，其中可能包含与特定发行有关的重要信息。招股说明书补充及任何相关的自由书面招股说明书还可能添加、更新或更改本招股说明书中或我们已通过引用纳入本招股说明书的任何文件中包含的信息。在本招股说明书、任何适用的招股说明书、任何相关的自由书面招股说明书或任何已通过引用纳入本招股说明书的文件中的任何声明之间存在冲突的程度上，具有较晚日期的文件中的声明修改或取代先前的声明。

本招股说明书或任何招股说明书补充资料中出现的信息仅截至各自日期有效，我们引用的任何信息仅截至被引用文件的日期有效，不论本招股说明书、适用的招股说明书补充资料或任何相关的自由书写招股说明书何时交付，或任何证券的销售时间。我们的业务、财务状况、经营业绩和前景自那些日期以来可能发生了重大变化。

您只能依赖本招股说明书中包含或引用的信息，或任何适用的招股说明书附录中包含的信息，或者根据特定发行活动授权使用的任何自由写作招股说明书中包含的信息。我们未授权任何人向您提供不同或额外的信息。

本招股说明书、任何招股补充文件或任何相关的自由书面招股说明，并非构成卖出或买入本招股说明书或适用的招股补充文件中描述的证券以外的任何证券的要约或要约买入，或在任何情况下或任何法域中对这些证券进行卖出或买入的要约或邀约均属违法。

根据SEC规则和法规的许可，本招股说明书作为一部分的注册声明包括了本招股说明书中未包含的附加信息。本招股说明书还包括了对所述文件中某些条款的摘要，但所有摘要均在其整体上通过参照实际文件而受到限制。您可以阅读注册声明以及我们向SEC提交的其他报告，并且您可以在SEC的网站上或本招股说明书中所述部分“”中描述的办公室获取本招股说明书中总结的实际文件副本（如在提交给SEC时）。您可以在哪里找到更多信息.”

我们在作为招股说明书的一部分而被作为展示文件提交的协议中所作的陈述、担保和契约仅为该等协议的各方（包括在某些情况下为了在该等协议各方之间分配风险）的利益而作，并不应被视为对您的陈述、担保或契约。而且，该等陈述、担保或契约仅在其作出时的日期准确。因此，不应依赖于这些陈述、担保和契约来准确代表我们事务的最新状况。

风险因素

投资我们的证券涉及高风险。适用于我们证券每一项发行的招股说明书将包含与投资asp isotopes公司相关的风险讨论。在做出投资我们证券的决定之前，您应仔细考虑招股说明书中“”标题下讨论的具体因素，以及招股说明书中包含或引用的所有其他信息，或包含或引用在本招股说明书中的信息。您还应考虑我们最近一份10-k表格年度报告中含有的“”标题下讨论的风险、不确定性和假设，可能会由我们随后提交给SEC的季度10-Q报告或我们已提交给SEC的8-k现行报告进行更新，所有这些已被引用在此，未来我们向SEC提交的报告可能会进行修订、补充或替代。我们描述的风险和不确定性并不是我们所面临的唯一挑战。我们目前尚不知晓的其他风险和不确定性，或我们目前认为不重要的风险和不确定性也可能影响我们的运营。这些风险发生可能会导致您在发行的证券中失去全部或部分投资。风险因素在我们的证券上投资涉及高风险。适用于每一次证券发行的招股说明书将包含与对asp isotopes 公司投资相关的风险讨论。在做出有关投资我们证券的决策之前，您应仔细考虑招股说明书中“”标题下讨论的特定因素，以及招股说明书中包含或引用的所有其他信息，或出现在本招股说明书中的信息。您还应考虑到我们最新的10-k表格年度报告中包含的“”标题下讨论的风险、不确定性和假设，可能会被我们随后提交的季度10-Q报告或我们已提交给SEC的当前8-k报告进行更新，所有这些信息均已被引用在此处，并且可能会在今后提交的报告中进行修订、补充或更新。我们描述的风险和不确定性并非我们所面临的唯一风险。我们目前未知或目前认为不重要的其他风险和不确定性，也可能会影响我们的运营。任何这些风险的发生可能导致您在所提供的证券中失去全部或部分投资。风险因素风险和不确定性的描绘并不是我们所面临的唯一挑战。目前我们不知道的其他风险和不确定性，或我们目前认为不重要的风险和不确定性，可能会对我们的运营产生影响。任何这些风险的发生可能导致您在提供的证券中失去全部或部分投资。

有关前瞻性声明之特别说明

本招股说明书，包括在此引用的文件，包含，任何招股说明书补充可能包含前瞻性声明。这些声明基于管理层关于未来事件、条件和成果的信念、期望和假设，以及当前对管理层可获得的信息。本招股说明书中包含的所有声明，包括在此引用的文件，以及任何招股说明书中，除历史事实声明外，均为前瞻性声明，包括但不限于关于我们能否以具有成本效益的方式完成、启用和成功运作同位素富集厂的能力；我们能否满足使用ASP技术或量子富集工艺可能生产的同位素相关监管要求的能力；我们能否获得同位素生产和分配的监管批准的能力；我们能否满足资本需求并获得资金用于运营和未来增长的能力；以及关于我们的业务战略、资本使用、经营成果和财务状况，以及未来业务计划和目标的声明。在某些情况下，您可以通过词语“可能”、“将”、“可能”、“应当”、“期待”、“打算”、“计划”、“预计”、“相信”、“估计”、“预测”、“项目”、“潜在”、“持续”、“进行中”或这些词语的否定形式，以及意图识别关于未来的声明，尽管并非所有前瞻性声明都包含这些词语。包含这些前瞻性声明讨论可在其他地方找到，其中包括从我们最近的年度10-K表格中引用的“业务”、“风险因素”和“管理层对财务状况和经营成果的讨论”部分，以及我们的10-Q季度报告，以及与之有关的任何修订，已向美国证券交易委员会提交。

由于前瞻性声明固有地受到风险和不确定性的影响，其中一些是无法预测或量化的，因此您不应将这些前瞻性声明视为对未来事件的预测。我们前瞻性声明中所反映的事件和情况可能无法实现或发生，实际结果可能会与前瞻性声明中所预测的产生重大差异。

本招股说明书，包括所引入的文件，还包含由独立方和我们提供的有关市场规模、增长以及我们所在行业其他数据的估计和其他统计数据。这些数据涉及多种假设和限制，我们提醒您不要过分重视这些估计。此外，关于我们未来绩效以及我们所处市场未来绩效的预测、假设和估计必然受到高度不确定性和风险的影响。

除非法律要求，我们不承担更新这些前瞻性声明的义务，也不会公开修订任何前瞻性声明以反映本招股说明书日期之后发生的事件或发展，即使将来有新信息可获得。所有前瞻性声明均受此警告性声明的完整约束。

使用资金

我们将保留对此处提供的证券销售所得款项的广泛自主裁量权。除非在我们授权向您提供的任何招股书补充说明书或任何相关的自由书面招股说明书中另有说明，我们目前打算将此处提供的证券销售所得款项用于营运资金和一般企业用途，包括资本支出、偿还债务、研发、销售和市场营销以及一般行政开支。我们也可能将部分证券销售所得款项用于收购或投资与我们业务互补的企业、产品和技术，尽管在本招股书日期之前，我们并没有针对任何此类收购或投资的当前计划、承诺或协议。在运用所得款项之前，我们可能将所得款项投资于短期、投资级、利息-bearing证券、存款证书或美国政府的直接或担保债务。

我们将在适用的招股说明书补充或自由写作招股说明书中规定，阐明我们计划如何利用根据招股说明书补充或自由写作招股说明书出售的证券所获得的净收益。

股本结构描述

下面对我们股本的描述是一个摘要，不代表完整内容。它是根据我们的公司证书和修正及重申的公司章程，或称“章程”，进行限定的。这一描述还总结了特拉华州法律的相关条款。我们的公司证书和章程作为展示文件提交给注册声明，本招股说明书是其中的一部分。我们鼓励您阅读我们的公司证书、章程和特拉华州法律的适用条款以获取更多信息。

总体来说

截至本招股说明书的日期，我们的公司章程授权发行5亿股普通股，每股面值为$0.01，和1000万股优先股，每股面值为$0.01，其中所有优先股都未指定。截至2024年5月30日，已发行和流通的普通股为51,762,833股，未发行和流通的优先股为0股。

Common Stock

The holders of our common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. The holders of our common stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our board of directors out of funds legally available, subject to preferences that may be applicable to preferred stock, if any, then outstanding. In the event of a liquidation, dissolution or winding up of our company, the holders of common stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. Our common stock has no preemptive or conversion rights or other subscription rights or redemption or sinking fund provisions.

Our common stock is traded on Nasdaq under the symbol “ASPI.”

The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC (formerly, American Stock Transfer & Trust Company, LLC). The transfer agent’s address is 6201 15th Avenue, Brooklyn, New York 11219.

Preferred Stock

Our Certificate of Incorporation authorizes our board of directors to establish one or more series of preferred stock. Unless otherwise required by law or any stock exchange, the authorized shares of preferred stock will be available for issuance without further action by the holders of our common stock. Our board of directors will be able to determine, with respect to any series of preferred stock, the powers (including voting powers), preferences and relative, participating, optional, conversion or other special rights, and the qualifications, limitations, or restrictions thereof. No shares of preferred stock have been issued or are outstanding as of the date of the filing of this registration statement. If we sell any series of preferred stock under this prospectus, we will file a certificate of designation relating to that series, which will be incorporated by reference into the registration statement of which this prospectus forms a part. The prospectus supplement will describe:

Anti-Takeover Matters in our Governing Documents and Under Delaware Law

Our Certificate of Incorporation and our Bylaws contain, and the DGCL contains, provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control, and enhance the ability of our board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an antitakeover effect and may delay, deter, or prevent a merger or acquisition by means of a tender offer, a proxy contest, or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders.

Authorized But Unissued Capital Stock

The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger, or otherwise.

Classified Board of Directors

Our Certificate of Incorporation provides that our board of directors be divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. Directors may only be removed from our board of directors for cause by the affirmative vote of at least 662∕3% of the voting power of all of our then-outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. In addition, our Certificate of Incorporation provides that, subject to the rights granted to one or more series of preferred stock then outstanding, any newly created directorship on the board of directors that results from an increase in the number of directors and any vacancies on our board of directors will be filled only by the affirmative vote of a majority of the remaining directors, even if less than a quorum, or by a sole remaining director. A director chosen to fill a position resulting from an increase in the number of directors will hold office until the next election of the director’s class and until the director’s successor is duly elected and qualified, or until the director’s earlier death, resignation or removal. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of us or changes in our management.

Delaware Anti-Takeover Law

We are subject to Section 203 of the DGCL, which is an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date that the person became an interested stockholder, unless the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a business combination includes a merger, asset or stock sale, or another transaction resulting in a financial benefit to the interested stockholder. Generally, an interested stockholder is a person who, together with affiliates and associates, owns 15% or more of the corporation’s outstanding voting stock or is the corporation’s affiliate or associate and was the owner of 15% or more of the corporation’s outstanding voting stock at any time within the three-year period immediately before the date of determination. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our board, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

No Cumulative Voting

Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. Our Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our stock entitled to vote generally in the election of directors are able to elect all of our directors.

Special Stockholder Meetings

Our Certificate of Incorporation provides that special meetings of our stockholders may be called at any time only by or at the direction of the board of directors, the chair of the board of directors or our Chief Executive Officer. Our Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management.

Director Nominations and Stockholder Proposals

Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder’s notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. Our Bylaws also specify requirements as to the form and content of a stockholder’s notice. Our Bylaws allow the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to influence or obtain control.

Stockholder Action by Written Consent

Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice, and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the certificate of incorporation provides otherwise. Our Certificate of Incorporation precludes stockholder action by written consent.

Amendment of Certificate of Incorporation or Bylaws

The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our Bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our Certificate of Incorporation described above.

The foregoing provisions of our Certificate of Incorporation and our Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares of common stock that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management or delaying or preventing a transaction that might benefit you or other minority stockholders.

Exclusive Forum

Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware be the sole and exclusive forum for: (1) any derivative action or proceeding brought on behalf of our company, (2) any action asserting a claim of breach of fiduciary duty owed by any director, officer, agent, or other employee or stockholder of our company to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim governed by the internal affairs doctrine, in each case subject to such Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. It will further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolutions of any complaint asserting a cause of action arising under the Securities Act. The exclusive forum clauses described above shall not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in such action. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Certificate of Incorporation.

Limitations of Liability and Indemnification

The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties, subject to certain exceptions. Our Certificate of Incorporation includes a provision that eliminates the personal liability of directors for monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions is to eliminate the rights of us and our stockholders, through stockholders’ derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation does not apply to any breaches of the director’s duty of loyalty, any acts or omissions not in good faith or that involve intentional misconduct or knowing violation of law, any authorization of dividends or stock redemptions or repurchases paid or made in violation of the DGCL, or for any transaction from which the director derived an improper personal benefit.

Our Bylaws generally provide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also are expressly authorized to carry directors’ and officers’ liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.

The limitation of liability, indemnification and advancement provisions in our Certificate of Incorporation and our Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.

We have entered into indemnification agreements with each of our directors and executive officers, under which we have agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of our company, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of our company. The indemnification agreements also set forth certain procedures, presumptions and remedies that will apply in the event of a claim for indemnification thereunder.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC such indemnification is against public policy and is therefore unenforceable.

DESCRIPTION OF DEBT SECURITIES

The following description summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities we may offer under this prospectus, the applicable prospectus supplement or free writing prospectus will describe the specific terms of any debt securities offered through that prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement or free writing prospectus may differ from the terms we describe below. Unless the context requires otherwise, whenever we refer to the “indentures,” we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.

We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus forms a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement, of which this prospectus forms a part, or will be incorporated by reference from reports that we file with the SEC.

The indentures will be qualified under the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”). We use the term “trustee” to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.

The following summary of material provisions of the senior debt securities, the subordinated debt securities and the indentures is subject to, and qualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete applicable indenture that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.

General

We will describe in the applicable prospectus supplement or free writing prospectus the terms of the series of debt securities being offered, including as applicable:

Conversion or Exchange Rights

We will set forth in the applicable prospectus supplement or free writing prospectus the terms on which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.

Consolidation, Merger or Sale

Unless we provide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate and must be a corporation organized and validly existing under the laws of any U.S. domestic jurisdiction. If the debt securities are convertible into or exchangeable for other securities of ours or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.

Events of Default under the Indenture

Unless we provide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:

We will describe in each applicable prospectus supplement or free writing prospectus any additional events of default relating to the relevant series of debt securities.

If an event of default with respect to debt securities of any series occurs and is continuing, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal due and payable immediately.

The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.

Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. Subject to the terms of the indentures, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:

These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement or free writing prospectus.

We expect to periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.

Modification of Indenture; Waiver

Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may enter into one or more supplemental indentures, without the consent of any holders, with respect to the following specific matters:

In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or as otherwise provided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:

Discharge

Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we can elect to be discharged from our obligations with respect to one or more series of debt securities.

In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium and interest on, the debt securities of the series on the dates payments are due. This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that all conditions precedent provided for in the indenture relating to the discharge have been complied with.

Form, Exchange and Transfer

We plan to issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement or free writing prospectus, in denominations of $1,000 and any integral multiple thereof. We may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depository named by us and identified in a prospectus supplement or free writing prospectus with respect to that series.

At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement or free writing prospectus, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.

Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement or free writing prospectus, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.

We will name in the applicable prospectus supplement or free writing prospectus the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.

If we elect to redeem the debt securities of any series, we will not be required to:

Information Concerning the Trustee

The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.

Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.

Payment and Paying Agents

Unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.

We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement or free writing prospectus any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.

All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.

Governing Law

We expect the indentures and the debt securities to be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.

Ranking of Debt Securities

The subordinated debt securities will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement or free writing prospectus. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.

The senior debt securities will rank equally in right of payment to any of our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.

Existing Long-Term Debt

On March 7, 2024, Quantum Leap Energy LLC, or “QLE,” our wholly owned subsidiary, issued convertible notes payable, or “Convertible Notes,” in the aggregate principal amount of $21,063,748 and received aggregate gross proceeds of $20,550,000.  The Convertible Notes are payable on demand on March 7, 2029 and bear an annual interest rate of 6% for the first year and 8% thereafter. Upon a qualified financing event, the Convertible Notes convert into the shares to be issued in that qualified financing event at a price per share equal to 80% of the share price issued subject to a valuation cap. Upon a qualified transaction, the noteholders may elect to receive either 1.5x the principal and accrued interest balance in cash or convert into common shares. The Convertible Notes are general unsecured obligations of QLE.  We are not a guarantor of the Convertible Notes. The Convertible Notes are subordinate in right of payment to all current and future indebtedness of QLE for borrowed money to banks, commercial finance lenders or other institutions regularly engaged in the business of lending money (whether or not such indebtedness is secured).

DESCRIPTION OF WARRANTS

The following description summarizes the material terms and provisions of the warrants that we may offer under this prospectus. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement or free writing prospectus, which may specify different or additional terms. Specific warrant agreements and warrant certificates related to warrants offered under this prospectus and any applicable prospectus supplement or free writing prospectus will contain additional important terms and provisions and will be incorporated by reference into the registration statement, of which this prospectus forms a part, from reports that we file with the SEC. 

General

We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. We plan to evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants.

We will describe in the applicable prospectus supplement the terms of the series of warrants, including as applicable:

DESCRIPTION OF UNITS

The following description summarizes the material terms and provisions of the units that we may offer under this prospectus. We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may issue units in such amounts and in as many distinct series as we deem appropriate under one or more unit agreements to be entered into between us and a bank or other financial institution, as a unit agent. The specific terms of any series of units offered will be described in the applicable prospectus supplement or free writing prospectus, and such terms may differ from the general description presented below. If we issue units, forms of unit agreements and unit certificates relating to such units will be incorporated by reference into this registration statement, of which this prospectus forms a part, from reports that we file with the SEC.

General

Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement, under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.

The applicable prospectus supplement may describe:

The provisions described in this section, as well as those described under “Description of Capital Stock,” “Description of Debt Securities” and “Description of Warrants” will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements.

PLAN OF DISTRIBUTION

We may sell these securities directly to one or more investors. We may also sell these securities through agents designated from time to time or to or through underwriters or dealers. We may sell these securities through “at the market” offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise. The applicable prospectus supplement and any related free writing prospectus will describe the terms of the offering of the securities, including, to the extent applicable:

We may distribute the securities from time to time in one or more transactions at:

Agents and Underwriters

We may designate agents who agree to use their reasonable efforts to solicit purchases of our securities for the period of their appointment or to sell our securities on a continuing basis. We will name any agent involved in the offering and sale of securities and we will describe any fees or commissions we will pay the agent in the applicable prospectus supplement.

If we use underwriters for a sale of securities, the underwriters will acquire the securities for their own account. The underwriters may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. Subject to certain conditions, the underwriters will be obligated to purchase all the securities of the series offered if they purchase any of the securities of that series. We may change from time to time any public offering price and any discounts or concessions the underwriters allow or reallow or pay to dealers. We may use underwriters with whom we have a material relationship. We will name any underwriter involved in the offering and sale of securities, describe any discount or other compensation and describe the nature of any material relationship in any applicable prospectus supplement. Only underwriters we name in the prospectus supplement will be underwriters of the securities offered by that prospectus supplement.

Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act. We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe their compensation.

We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities related to offerings under this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Underwriters, dealers and agents may engage in transactions with or perform services for us in the ordinary course of their businesses.

Trading Markets and Listing of Securities

Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is currently listed on the Nasdaq Stock Market. We may elect to list or qualify for trading any other class or series of securities on any securities exchange or other market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.

At-the-Market Offerings

To the extent that we make sales through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms of a sales agency financing agreement or other at-the-market offering arrangement between us and the underwriters or agents. If we engage in at-the-market sales pursuant to any such agreement, we will issue and sell our securities through one or more underwriters or agents, which may act on an agency basis or a principal basis. During the term of any such agreement, we may sell securities on a daily basis in exchange transactions or otherwise as we agree with the underwriters or agents. Any such agreement will provide that any securities sold will be sold at prices related to the then prevailing market prices for our securities. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time. Pursuant to the terms of the agreement, we may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase blocks of our common stock or other securities. The terms of any such agreement will be set forth in more detail in the applicable prospectus supplement.

Stabilization Activities

Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of these activities at any time.

Passive Market Making

Any underwriter who is a qualified market maker on the Nasdaq Stock Market may engage in passive market making transactions in securities listed on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. A passive market maker must comply with applicable volume and price limitations and must be identified as a passive market maker. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security. If all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.

LEGAL MATTERS

Unless otherwise indicated in the applicable prospectus supplement, the validity of any common stock, preferred stock, debt securities, warrants or units offered under this prospectus and any supplement hereto will be passed upon for us by Blank Rome LLP, Dallas, Texas.

EXPERTS

The consolidated balance sheets of ASP Isotopes Inc. and Subsidiaries as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern. Such financial statements have been incorporated by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing.

INFORMATION INCORPORATED BY REFERENCE

SEC rules permit us to incorporate information by reference into this prospectus and any applicable prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus and any applicable prospectus supplement, except for information superseded by information contained in this prospectus or the applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and any applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with the SEC (other than information in such documents that is deemed to be furnished and not filed). These documents contain important information about us and our business and financial condition.

All documents that we file (other than information in such documents that is deemed to be furnished and not filed), pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial filing of the registration statement, of which this prospectus forms a part, and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file ((other than information in such documents that is deemed to be furnished and not filed) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents.

本说明书中包含的任何声明，或纳入本说明书或适用的说明书附件并被视为纳入其中的文件中的任何声明，应被视为已经就本说明书及该适用的说明书附件的目的进行了修改或取代，至这样的适用的说明书附件中包含的声明，或任何其他随后提交的文件中包含的声明，该文件也被视为纳入本说明书及该适用的说明书附件，修改或取代了这样更早的声明。经修改或取代的声明不得被视为（除非经过修改或取代）构成本说明书或该适用的说明书附件的一部分。

已通过引用纳入的文件可免费向我们获取，所有板块均可获得，不包括所有附录。

有意投资者可以通过书面或电话向我们的行政办公室请求免费获取并入本招股说明书和适用招股说明书的参考文件。

asp isotopes公司。

华盛顿特区宾夕法尼亚大道1101号，300套房间

华盛顿特区20004

(202) 756-2245

注意：公司秘书

                您也可以免费在SEC网站上访问这些文件。 www.sec.gov 或者在我们的网站www.aspisotopes.com上。在SEC的网站上或者通过SEC的网站可以访问的信息，或者在我们的网站上可以访问的信息，均不构成本招股说明的一部分，也不被作为本招股说明的引用，您不应将我们网站上的信息视为本招股说明的一部分。

在哪里寻找更多信息

根据证监会规定，该招股说明书省略了包含在注册声明中的某些信息，而本招股说明书是其中的一部分，以及其附件。由于本招股说明书可能没有包含您认为重要的所有信息，我们建议您查看这些文件的全部内容。如果我们已经将某份合同、协议或其他文件作为注册声明的附件提交，而本招股说明书是其中的一部分，请阅读附件以更全面地了解涉及的文件或事项。本招股说明书中的每一项声明，包括上述引用的陈述，有关合同、协议或其他文件的声明都应以参考实际文件而整体合格。

我们受《交易所法》的信息披露要求约束，根据这些要求，我们提交年度、季度和最新报告、代理声明、信息声明以及其他信息给SEC。您可以在SEC的网站或我们的网站上阅读和复制我们提交给SEC的任何材料。 www.sec.gov 或者在我们的网站 www.aspisotopes.com上查看。在SEC的网站或我们的网站上包含或可以通过的信息不是本招股说明书的组成部分，也不被纳入参考，您不应将我们网站上的信息视为本招股说明书的一部分。

股份

普通股

Canaccord Genuity